scientifyRESEARCH
research funding database

RESEARCH FUNDING

This opportunity is currently closed.

Sign up for Content alerts to stay informed when this or related funding opportunities are posted.

HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) (worldwide)

Share this post

Logo of scientifyRESEARCH and Enago "Author First, Quality First" scientifyRESEARCH recommends English editing and author support services from Enago.

The HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) from the National Institutes of Health (NIH) supports the discovery of strong candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. The resulting biomarkers or biomarker signatures may be focused on a single pain condition or on several pain conditions with common underlying pathophysiology. Applications are open to researchers at research institutions in the USA and worldwide. Applicants may apply for up to 1.5 million USD/year for up to 5 years.

Opportunity number: RFA-NS-24-018.

Letters of intent are due on June 10, 2023 and full applications are due on July 10, 2023.

Full application due:
July 10, 2023

Adverts. Premium members do not see Google Ads.

Please Login / Subscribe to our premium membership to see the content. Sign up to Free trial to see detailed funding information.

non member

Sign-up for our monthly
research funding newsletter

you can unsubscribe at any time

Be the first to know

Sign-up for Personalized Grant Alerts

Logo3